 Filgrastim
"Filgrastim" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant granulocyte colony-stimulating factor (G-CSF) that is used in the treatment and prevention of NEUTROPENIA, preparation and collection of blood progenitor cells, and for use in PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
| Descriptor ID |
D000069585
|
| MeSH Number(s) |
D12.644.276.374.410.240.350.500 D12.776.395.240.200.500 D12.776.467.374.410.240.350.500 D23.529.374.410.240.350.500
|
| Concept/Terms |
Filgrastim- Filgrastim
- G-CSF Recombinant, Human Methionyl
- G CSF Recombinant, Human Methionyl
- Recombinant-Methionyl Human Granulocyte Colony-Stimulating Factor
- Recombinant Methionyl Human Granulocyte Colony Stimulating Factor
- R-metHuG-CSF
- R metHuG CSF
Zarxio- Zarxio
- Filgrastim-Sandoz
- Filgrastim Sandoz
- FilgrastimSandoz
- Filgrastim-Sndz
- Filgrastim Sndz
|
Below are MeSH descriptors whose meaning is more general than "Filgrastim".
Below are MeSH descriptors whose meaning is more specific than "Filgrastim".
This graph shows the total number of publications written about "Filgrastim" by people in this website by year, and whether "Filgrastim" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2000 | 0 | 2 | 2 | | 2004 | 0 | 2 | 2 | | 2020 | 1 | 0 | 1 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Filgrastim" by people in Profiles.
-
Liu A, Xuan A, Socal M, Anderson G, Anderson KE. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019. J Manag Care Spec Pharm. 2024 Jan; 30(1):15-21.
-
Hussaini SMQ, Gupta A, Anderson KE, Ballreich JM, Nicholas LH, Alexander GC. Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019. JAMA Netw Open. 2022 03 01; 5(3):e221117.
-
Bhardwaja B, Klocke S, Ekinci E, Jackson A, Kono S, Olson KL. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System. BioDrugs. 2022 Jan; 36(1):1-11.
-
Socal MP, Anderson KE, Sen A, Bai G, Anderson GF. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim. Value Health. 2020 04; 23(4):481-486.
-
Couban S, Aljurf M, Lachance S, Walker I, Toze C, Rubinger M, Lipton JH, Lee SJ, Szer J, Doocey R, Lewis ID, Huebsch L, Howson-Jan K, Lalancette M, Almohareb F, Chaudhri N, Ivison S, Broady R, Levings M, Fairclough D, Devins G, Szwajcer D, Foley R, Smith C, Panzarella T, Kerr H, Kariminia A, Schultz KR. Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study. Biol Blood Marrow Transplant. 2016 08; 22(8):1410-1415.
-
Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE, Walsh TJ, Gergis U. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1808-14.
-
Skaznik-Wikiel ME, McGuire MM, Sukhwani M, Donohue J, Chu T, Krivak TC, Rajkovic A, Orwig KE. Granulocyte colony-stimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy. Fertil Steril. 2013 Jun; 99(7):2045-54.e3.
-
Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, Stern J, Christos PJ, Mathews L, Shore TB, Zafar F, Pekle K, Xiang Z, Ely S, Skerret D, Chen-Kiang S, Coleman M, Lane ME. Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clin Cancer Res. 2013 Mar 15; 19(6):1534-46.
-
Neid JM, Schooley RT, Campbell TB. Stimulation of Kaposi's sarcoma-associated herpesvirus viremia during hematopoietic stem cell mobilization with filgrastim. Am J Hematol. 2004 Dec; 77(4):410-2.
-
Campbell TB, Rapaport E, Schooley RT, Kuritzkes DR. Increased replication of HIV-1 minor variants during hematopoietic stem-cell mobilization with filgrastim. J Infect Dis. 2004 Jul 15; 190(2):257-66.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|